S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
NASDAQ:ARMO

ARMO BioSciences (ARMO) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$49.98
$49.98
50-Day Range
$49.98
$49.98
52-Week Range
$25.10
$57.19
Volume
N/A
Average Volume
201,363 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ARMO stock logo

About ARMO BioSciences Stock (NASDAQ:ARMO)

ARMO BioSciences, Inc., an immuno-oncology company, develops a pipeline of novel product candidates that activate the immune system of cancer patients to recognize and eradicate tumors in the United States. Its lead product candidate is AM0010, a long acting form of human interleukin-10 that is in Phase III randomized pivotal clinical trial for the treatment of pancreatic ductal adenocarcinoma. The company is also developing AM0010 that has completed Phase I/Ib clinical trial for the treatment of non-small cell lung cancer, renal cell carcinoma, colorectal cancer, and melanoma and breast cancer. In addition, it is developing AM0001, a monoclonal antibody against programmed cell death protein-1 checkpoint inhibitor; AM0015, a recombinant human interleukin-15; AM0012, a recombinant human Interleukin-12; and AM0003, a monoclonal antibody against leukocyte activating gene-3 protein program. The company was formerly known as Targenics, Inc. and changed its name to ARMO BioSciences, Inc. in December 2012. ARMO BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

ARMO Stock News Headlines

Pacific Biosciences of California Inc
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Armor Protective Packaging
Best Armor Sets In V Rising, Ranked
Codiak BioSciences Inc (CDAKQ)
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
HR Acuity Named to Inc. 5000 Annual List
Eli Lilly and Co
How To Farm Pristine Hide In V Rising
See More Headlines
Receive ARMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARMO BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/02/2018
Today
4/17/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARMO
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Peter Van Vlasselaer (Age 59)
    Founder, Pres, CEO & Director
  • Mr. Herbert C. Cross (Age 46)
    Chief Financial Officer
  • Dr. Joseph Leveque (Age 57)
    Chief Medical Officer
  • Dr. Martin Oft (Age 51)
    Founder and VP of Pre-Clinical & Clinical Devel.
  • Dr. Russell T. Kawahata (Age 64)
    VP of Technical Operations

ARMO Stock Analysis - Frequently Asked Questions

How were ARMO BioSciences' earnings last quarter?

ARMO BioSciences, Inc. (NASDAQ:ARMO) announced its quarterly earnings data on Monday, April, 2nd. The company reported ($9.62) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by $9.17.

What other stocks do shareholders of ARMO BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ARMO BioSciences investors own include Standex International (SXI), Exelixis (EXEL), Tesla (TSLA), NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Bausch Health Companies (BHC), EyePoint Pharmaceuticals (EYPT), Madrigal Pharmaceuticals (MDGL) and Progenics Pharmaceuticals (PGNX).

When did ARMO BioSciences IPO?

ARMO BioSciences (ARMO) raised $100 million in an initial public offering on Friday, January 26th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Baird was co-manager.

This page (NASDAQ:ARMO) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners